CA-ESRI
10.3.2022 14:02:10 CET | Business Wire | Press release
Governments and businesses across the world are pledging to adopt more sustainable and equitable practices. Many are also working to limit activities that contribute to climate change. To support these efforts, Esri , the global leader in location intelligence, in partnership with Impact Observatory and Microsoft, is releasing a globally consistent 2017–2021 global land-use and land-cover map of the world based on the most up-to-date 10-meter Sentinel-2 satellite data. In addition to the new 2021 data, 10-meter land-use and land-cover data for 2017, 2018, 2019, and 2020 is included, illustrating five years of change across the planet.
This digital rendering of earth's surfaces offers detailed information and insights about how land is being used. The map is available online to more than 10 million users of geographic information system (GIS) software through Esri's ArcGIS Living Atlas of the World , the foremost collection of geographic information and services, including maps and apps.
"Accurate, timely, and accessible maps are critical for understanding the rapidly changing world, especially as the effects of climate change accelerate globally," said Jack Dangermond, Esri founder and president. "Planners worldwide can use this map to better understand complex challenges and take a geographic approach to decisions about food security, sustainable land use, surface water, and resource management."
Esri released a 2020 global land-cover map last year as well as a high-resolution 2050 global land-cover map , showing how earth's land surfaces might look 30 years from now. With the planned annual releases, users will have the option to make year-to-year comparisons for detecting change in vegetation and crops, forest extents, bare surfaces, and urban areas.
These maps also provide insights about locations with distinctive land use/land cover, as well as human activity affecting them. National government resource agencies use land-use/land-cover data as a basis for understanding trends in natural capital, which helps define land-planning priorities and determine budget allocations.
Esri's map layers were developed with imagery from the European Space Agency (ESA) Sentinel-2 satellite, with machine learning workflows by Esri Silver partner Impact Observatory and incredible compute resources from longtime partner Microsoft. The Sentinel-2 satellite carries a range of technologies including radar and multispectral imaging instruments for land, ocean, and atmospheres, enabling it to monitor vegetation, soil and water cover, inland waterways, and coastal areas.
"World leaders need to set and achieve ambitious targets for sustainable development and environmental restoration," said Steve Brumby, Impact Observatory cofounder and CEO. "Impact Observatory [and] our partners Esri and Microsoft are once again first to deliver an annual set of global maps at unprecedented scale and speed. These maps of changing land use and land cover provide leaders in governments, industry, and finance with a new AI [artificial intelligence]-powered capability for timely, actionable geospatial insights on demand."
Esri and Microsoft have released this 10-meter-resolution time-series map under a Creative Commons license to encourage broad adoption and ensure equitable access for planners working to create a more sustainable planet. Users can manipulate the map layers and other data layers with GIS software to create more dynamic visualizations.
In addition to being freely available in ArcGIS Online as a map service, these resources are also available for download and viewing. To explore the new 2021 global land-use/land-cover map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory develops AI-powered, on-demand, geospatial data that maps changing land use and land cover at unprecedented scale and speed. Impact Observatory provides world leaders in governments, industry, and finance with timely, actionable, data-driven insights for sustainability and environmental risk analysis. Impact Observatory is a U.S. technology company based in Washington, D.C.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom